Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying ...
Collaboration will evaluate Scenic's first-in-class PLA2G15 inhibitor program in Parkinson's diseaseLeveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to test ...
They scuffled even as their colleagues were extinguishing the blaze.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results